Search results for "marginal zone lymphoma"

showing 3 items of 33 documents

Splenic Marginal Zone Lymphoma: French Registries Population-Based Treatment and Survival Analyses (2002-2014)

2020

Background. Splenic Marginal Zone Lymphoma (SMZL) is a rare indolent B-cell lymphoma characterized by a massive splenomegaly and a moderate lymphocytosis. There is no standard of care for SMZL so far. The treatment is indicated if constitutional symptoms, massive splenomegaly and/or cytopenia, after a watch and wait period that is highly variable. Rituximab with or without chemotherapy, chemotherapy, and splenectomy are valid treatment approaches. Our objectives were to describe the characteristics of the patients with SMZL retrospectively collected from a French population database, to analyze the treatments received in first line (Tt1) and in second line (Tt2) in term of efficacy, and to …

medicine.medical_specialtyCytopeniaLymphocytosisbusiness.industryConstitutional symptomsmedicine.medical_treatmentImmunologySplenectomyCell BiologyHematologymedicine.diseaseBiochemistryLymphomaInternal medicinemedicineRituximabSplenic marginal zone lymphomaStage (cooking)medicine.symptombusinessmedicine.drugBlood
researchProduct

Salmon-colored and white areas on dermoscopy as supportive findings in the diagnosis of primary cutaneous marginal zone lymphoma

2019

medicine.medical_specialtyWhite (horse)business.industryCancerlymphomaArticlesDermatologymedicine.diseaseDermatologyLymphomaOncologyRL1-803GeneticsmedicinecancerPrimary cutaneous marginal zone lymphomadermoscopybusinessMolecular BiologyDermatology Practical & Conceptual
researchProduct

BENDAMUSTINE IN ASSOCIATION WITH RITUXIMAB AS SALVAGE THERAPY FOR SPLENIC MARGINAL ZONE LYMPHOMA

2010

At present, a prospectively validated treatment for SMZL is lacking. Despite this fact, splenectomy is still deemed to be the best choice for patients requiring treatment. Nevertheless, the high fraction of patients achieving a clinical response following splenectomy eventually relapses or progresses

splenic marginal zone lymphomabendamustineSettore MED/15 - Malattie Del Sangue
researchProduct